menu search

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights
Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027 SEATTLE and CAMBRIDGE, United Kingdom, March 06, 2023 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet […] The post Eliem Therapeutics Reports Fourth Quarter an... Read More
Posted: Mar 6 2023, 21:10
Author Name: forextv
Views: 082177

Search within

Pages Search Results: